Skip to main content
Equibles
SANA logo

SANA · Sana Biotechnology, Inc.

Track SANA — free

Use SANA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SANA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.74 -0.36 (-8.78%) At close · Aug 20
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to our ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$1.12B
Shares
299.36M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.74 Open$4.06 Day$3.73–4.08 52W close$2.68–5.92 Avg vol 30d2.6M Short int42.1M · 14.1% float · 16.3d Short vol62% Last earningsMay 8, 2025 DataFeb 2021–Aug 2026 Filing10-Q · Aug 10

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg +10%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 33%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +17%
trailing
6-month return −11%
trailing
YTD return −8%
this year
Relative strength −22%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
14.08% of float · ▲ +6.1% MoM · 16.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
211 holders — near 3-yr high, broad support
Squeeze score 87
high risk · 0–100
Fundamentals
Strong
EPS growth +17%
Y/Y
Free cash flow $-144.8M
Balance sheet $71.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −55%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
33% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
14.08% of float · ▲ +6.1% MoM · 16.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
211 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $4 · 33% Range high $6
vs 200-day avg +1% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Non-GAAP operating cash burn non-GAAP $69.3M six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SANA
Sana Biotechnology, Inc.
this stock
$1.12B -8.1% — — 14.1%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
211
% held
61.8%
Net QoQ
+20.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
141
View
Short & Settlement
Short Interest Rising
Shares short
42.1M
Days to cover
16.3d
Change
+2.4M sh
View
Short Volume
Short vol %
62%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
75.5K
Value
$240.2K
As of
Jul 27, 2026
View
Off-Exchange
Off-exchange %
35.8%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-244.2M
EPS diluted
$-0.96
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
15
View
Proposed Sales
Value
$237.0K
Shares
75.0K
Filed
Feb 18, 2025
View
Exempt Offerings
Offering
$821.1M
Filed
Jun 26, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View

Performance

5D 20D 120D MTD YTD
SANA +1.9% +16.5% -11.2% +19.5% -8.1%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +3.9% +13.2% -22.3% +17.4% -19.9%
Key facts CIK 1770121 CUSIP 799566104 13F (30d) 196 filings 196 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)